Acetylcholine Receptor Modulating Antibody
Myasthenia Gravis (MG) , ARUP #99521, Antrim #80130, EPIC: LAB5923, SOFT: XARMO
Specimen Collection Criteria
Collect (preferred specimen): One Gold-top SST tube.
Also acceptable: One plain Red-top tube.
Physician Office/Drawsite Specimen Preparation
Let specimen clot 30-60 minutes then centrifuge to separate serum from cells within two hours of collection. Transfer serum to a plastic transport tube and refrigerate (2-8°C or 36-46°F).
Preparation for Courier Transport
Transport: 0.5 mL serum, refrigerated (2-8°C or 36-46°F). (Min: 0.3 mL)
- Hemolyzed specimens.
- Severly lipemic specimens.
- Specimens not collected and processed as indicated.
Ambient: 2 hours
Refrigerated: 7 days
Frozen: 1 month (avoid multiple freeze-thaw cycles)
Sunday - Friday.
Results available in 3-8 days.
Negative: 0-45% modulation.
Positive: 46% or greater modulation.
Semi-Quantitative Flow Cytometry.
Approximately 85-90% of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibody. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair AChR binding to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15% of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibody.
ARUP #99521, Antrim #80130, EPIC: LAB5923, SOFT: XARMO
Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.
This directory currently reflects information only for specimens collected and/or processed at the
Farmington Hills, Grosse Pointe, Royal Oak, and Troy campuses.